Mometasone furoate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1987
- First approval year
- 1987
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Mometasone furoate
- Molecular weight
- 521.44
- Structure (SMILES)
- C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
- asmanex
- Asmanex
- asmanex hfa
- Asmanex hfa
- asmanex twisthaler
- Asmanex twisthaler
- elocon
- Elocon
- mometasone furoate
- Mometasone furoate
- mometasone furoate component of dulera
- Mometasone furoate component of dulera
- mometasone furoate component of lyr 220 active
- Mometasone furoate component of lyr-220 active
- mometasone furoate component of ryaltris
- Mometasone furoate component of ryaltris
- nasonex
- Nasonex
- nasonex 24hr allergy
- Nasonex 24hr allergy
- sinuva
- Sinuva
- (11.BETA.,16.ALPHA.)-9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
- 11 beta 16 alpha 9 21 dichloro 17 2 furanylcarbonyl oxy 11 hydroxy 16 methylpregna 1 4 diene 3 20 dione
- 9 21 dichloro 11β 17 dihydroxy 16α methylpregna 1 4 diene 3 20 dione 17 2 furoate
- 9,21-Dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
- dulera component mometasone furoate
- DULERA COMPONENT MOMETASONE FUROATE
- elocon
- Elocon
- Elocon ointment
- las 41002
- LAS-41002
- las41002
- LAS41002
- lyr 210
- lyr 220 active component mometasone furoate
- Lyr-210
- LYR-210
- LYR-220 ACTIVE COMPONENT MOMETASONE FUROATE
- lyr210
- LYR210
- mometasone furoate
- Mometasone furoate
- Mometasone Furoate
- MOMETASONE FUROATE
- Mometasone Furoate (MF)
And 45 more, listed on the interactive page.
- CAS registry numbers
- 83919-23-7
- ChEMBL ID
- CHEMBL1161
- InChIKey
- WOFMFGQZHJDGCX-ZULDAHANSA-N
- PubChem compound IDs
- 441336
- FDA ingredient codes (UNII)
- 04201GDN4R
- D07AC13
- D07XC03
- R01AD09
- R03BA07
Sources for recorded values
- 30145
- 108118
- Applicant
- ORGANON LLC
- Approval date
- 30 Mar 2005
- Application number
- NDA021067
- Patents
- 7
- Designations
- 1
- Earliest recorded loss of exclusivity
- 24 Nov 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
Administration routes
- Parenteral
- topical
Mechanisms of action
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Psoriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Skin Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Hypertrophy
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002460
- Subject identifier
- D006984
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003956
- Subject identifier
- D006255
- Condition
- Alopecia Areata
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Eosinophilic Esophagitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004232
- Subject identifier
- D057765
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005854
- Subject identifier
- D006255
- Condition
- Rhinitis, Allergic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005854
- Subject identifier
- D065631
- Condition
- Pemphigoid, Bullous
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007187
- Subject identifier
- D010391
- Condition
- Otitis Media with Effusion
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0007415
- Subject identifier
- D010034
- Condition
- Sinusitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Nasal Polyps
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000391
- Subject identifier
- D009298
- Condition
- Rhinitis, Allergic, Perennial
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001417
- Subject identifier
- D012221
- Condition
- Psoriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001494
- Subject identifier
- D011565
- Condition
- Nasal Obstruction
- Highest recorded phase
- 4
- Condition identifier
- HP:0001742
- Subject identifier
- D015508
- Condition
- Lung Diseases, Obstructive
- Highest recorded phase
- 4
- Condition identifier
- HP:0006536
- Subject identifier
- D008173
- Condition
- Nasal Polyps
- Highest recorded phase
- 4
- Condition identifier
- HP:0100582
- Subject identifier
- D009298
- Condition
- Asthma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Hypersensitivity
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Anemia, Sickle Cell
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0011382
- Subject identifier
- D000755
- Condition
- Radiodermatitis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0043771
- Subject identifier
- D011855
And 2 more, listed on the interactive page.
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000701
- Condition identifier
- EFO_0002460
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003918
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003956
- Condition identifier
- EFO_0003963
- Condition identifier
- EFO_0004192
- Condition identifier
- EFO_0004232
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005854
- Condition identifier
- EFO_0007187
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007415
- Condition identifier
- EFO_0007486
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009364
- Condition identifier
- EFO_0009837
- Condition identifier
- EFO_1000391
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001417
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 2
- Condition identifier
- EFO_1002029
- Highest recorded phase
- 3
- Condition identifier
- HP_0000458
- Highest recorded phase
- 3
- Condition identifier
- HP_0000689
- Condition identifier
- HP_0000964
- Highest recorded phase
- 2
- Condition identifier
- HP_0001742
- Condition identifier
- HP_0001742
- Highest recorded phase
- 4
- Condition identifier
- HP_0002091
- Highest recorded phase
- 1
And 29 more, listed on the interactive page.
- Event
- adrenal suppression
- Reports
- 29
- Reporting signal score
- 88.0686
- Event
- anosmia
- Reports
- 63
- Reporting signal score
- 138.781
- Event
- asthma
- Reports
- 486
- Reporting signal score
- 896.2
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 20
- Reporting signal score
- 79.2309
- Event
- blood count abnormal
- Reports
- 65
- Reporting signal score
- 81.3107
- Event
- chest discomfort
- Reports
- 219
- Reporting signal score
- 203.674
- Event
- coma
- Reports
- 183
- Reporting signal score
- 232.823
- Event
- cough
- Reports
- 618
- Reporting signal score
- 666.198
- Event
- cushing's syndrome
- Reports
- 46
- Reporting signal score
- 89.4701
- Event
- diarrhoea
- Reports
- 41
- Reporting signal score
- 125.406
- Event
- dysphonia
- Reports
- 147
- Reporting signal score
- 176.657
- Event
- dyspnoea
- Reports
- 1,171
- Reporting signal score
- 1,142.62
- Event
- gastrooesophageal reflux disease
- Reports
- 293
- Reporting signal score
- 465.463
- Event
- incorrect dose administered by product
- Reports
- 27
- Reporting signal score
- 99.525
- Event
- injection site pain
- Reports
- 2
- Reporting signal score
- 79.9229
- Event
- nasal congestion
- Reports
- 153
- Reporting signal score
- 201.326
- Event
- nasal discomfort
- Reports
- 48
- Reporting signal score
- 112.983
- Event
- nasal polyps
- Reports
- 52
- Reporting signal score
- 161.452
- Event
- pneumonia aspiration
- Reports
- 176
- Reporting signal score
- 357.057
- Event
- polycystic ovaries
- Reports
- 26
- Reporting signal score
- 78.2679
- Event
- poor quality device used
- Reports
- 1,604
- Reporting signal score
- 8,503.71
- Event
- poor quality drug administered
- Reports
- 68
- Reporting signal score
- 169.903
- Event
- poor quality product administered
- Reports
- 79
- Reporting signal score
- 250.766
- Event
- product availability issue
- Reports
- 46
- Reporting signal score
- 111.741
- Event
- product dose omission issue
- Reports
- 322
- Reporting signal score
- 534.113
And 16 more, listed on the interactive page.
- NCT00224523
- NCT00720382
- NCT00732368
- NCT00779545
- NCT00779740
- NCT01135134
- NCT01165424
- NCT01287364
- NCT01470053
- NCT01700192
- NCT02498509
- NCT00358527
- NCT00453063
- NCT00468312
- NCT00491504
- NCT00552110
- NCT00784732
- NCT01038427
- NCT01523236
- NCT01673659
- NCT01850823
- NCT02125253
- NCT02318303
- NCT02478398
- NCT02557269
And 99 more, listed on the interactive page.
- Route
- Topical
- How often
- Once daily
- Apply a thin film to the affected skin areas
- Discontinue when control is achieved
- Do not use with occlusive dressings unless directed by a physician
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 93.81
- Calculated partition coefficient (ALogP)
- 4.87
- Calculated partition coefficient (XLogP)
- 3.9
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 35
- Molecular formula
- C27H30Cl2O6
- Monoisotopic mass
- 520.1419441
- Natural product
- Yes
- 0713-0634
- 0713-0635
- 10599-003
- 13668-527
- 21922-071
- 21922-072
- 45802-118
- 45802-119
- 45802-257
- 63187-288
- 63187-432
- 65162-891
- 68462-192
- 68462-385
- 71205-413
- 78206-111
- 78206-112
- 78206-113
- 78206-114
- 78206-115
- 78206-125
- 78206-126
- 78206-127
- 85766-181
- 50090-1633
And 17 more, listed on the interactive page.
- Recorded assays
- 1,275
- Active assays
- 183
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
- Dermatologic Agents
- Anti-Allergic Agents
Related records
Trials (201)
- 4"S" - Seasonal Symptoms Suppression Study
- 480 Biomedical Sinus Drug Depot
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
- A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
- A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)
- A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
- A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
- A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers
- A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
- A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
- A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
- A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis
- A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test
- A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test
- A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
Approved for (6)
- Allergic rhinitis
- Asthma
- Nasal cavity polyp
- Obstructive lung disease
- Seasonal allergic rhinitis
- Skin disorder
In development for (17)
- Allergic disease Phase 1
- Alopecia areata Early phase 1
- Atopic eczema Phase 2
- Breast cancer Phase 3
- Bullous pemphigoid Phase 2
- Chronic obstructive pulmonary disease Phase 3
- COVID-19 Phase 3
- Eosinophilic esophagitis Phase 2
- Obstructive sleep apnea syndrome Phase 3
- Otitis media with effusion Early phase 1
- Palmoplantar pustulosis Phase 2
- Perennial allergic rhinitis Phase 3
- Psoriasis Phase 2
- Radiodermatitis Phase 2
- Sickle cell disease Phase 2
- Sinusitis Phase 3
- Spinal cord injury Phase 1
Targets (1)
- NR3C1 Glucocorticoid receptor agonist